🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11254739

Anti-human migration stimulating factor (MSF) and uses thereof

HUMANITAS MIRASOLE S.P.A. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11246926

Polynucleotides encoding anti-C1s antibodies

Bioverativ USA Inc. · Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11242339

Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflam

United States Government as represented by the Department of Veterans Affairs · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11241512

Stabilized radio-labeled anti-CD45 immunoglobulin compositions

Actinium Phamaceuticals, Inc. · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11235059

Afucosylated anti-FGFR2IIIB antibodies

Five Prime Therapeutics, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11229630

Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

Olema Pharmaceuticals, Inc. · Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11220535

Anti-BCMA chimeric antigen receptors

Cartesian Therapeutics, Inc. · Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11208456

Anti-KRAS-G12D T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11207394

Anti-mutated KRAS T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11207379

Peptides with anti-cancer activity

IDP DISCOVERY PHARMA, S.L. · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11191843

Multi-arm targeting anti-cancer conjugate

BrightGene Bio-Medical Technology Co., Ltd. · Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11186625

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11186611

Peptide with anti-obesity and anti-diabetes activity and use thereof

CAREGEN CO., LTD. · Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11185585

Methods and compositions for improving antiangiogenic therapy with anti-integrins

The Regents of the University of California · Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11180540

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11180492

Anti-parasitic compounds and uses thereof

The Regents of the University of California · Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11174316

Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11174283

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11168144

Activatable anti-PDL1 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11161876

Anti-inflammatory nanofibers

Northwestern University · Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11161826

Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent

ACADIA Pharmaceuticals Inc. · Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11155633

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11155621

Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11149025

Anti-cancer compounds

The Regents of the University of California · Granted Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted